🫧 Edgar looked up Krystal Biotech, Inc. ($KRYS). Last filing: 8-K (2.02 Results of Operations and Financial Condition), 2026-08-03. 10 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $389.1M (FY2025). Experience: revenue up 33.9% on the year; operating margin 41.5%, up from 22.6%. Soundness: equity 91.4% of assets, return on equity 16.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $411.1M and $660.8M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 41.5% against a -15.8% median; growth 33.9% against 21.4%.
| Fiscal year end | 2025-12-31 |
| Revenue | $389M |
| Revenue, on the year | 33.9% |
| Revenue, a year over the record | — |
| Operating margin | 41.5% |
| Operating margin, prior year | 22.6% |
| Net margin | 52.6% |
| Research and development | $58M · 14.9% of revenue |
| Free cash flow | $189M |
| Cash | $496M |
| Total debt | — |
| Equity of assets | 91.4% |
| Return on equity | 16.8% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $7.08 |
| Book value per share | $40.72 |
| Revenue per share | $12.99 |
| Shares outstanding | 29,951,000 |
| Audited years read | 5 |
Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).
Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt.
Sailing speed follows growth: 33.9% a year crosses the harbor in 30 seconds.
No warning signs on the measures below.
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
| Cash conversion (operating cash ÷ revenue) | 51.6% |
| Growth speed (3 years, per year) | 33.9% |
| Revenue swing (std-dev of yearly growth) | — |
| Speed and steadiness | — |
| Common dividend | none |
| Equity of assets | 91.4% |
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company
Or tap watch on any row above. One note the day they file, from Edgar, each with a one-click stop link. Handled to EU GDPR and Japan APPI standards.
On Bluesky: follow Edgar & Edgarette.
Priced live by the same engine as our estimator, from the catalogue at wholesale.
Price the printing · Open the full estimator
✦ Build the kit yourselfMost buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.
Jenny Huang Goodman MPA MSc MHSA, Principal
Book a time (757) 390-0424Nine boards reading every SEC filing the day it lands, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.